Health Maintenance in the Inflammatory Bowel Disease Patient

Gastroenterology Clinics of North America

Volumn 41, Issue 2, 2012, Pages 325-337

  Sinclair, Jennifer A ^a   Wasan, Sharmeel K ^a,b   Farraye, Francis A ^a,b  

^a BOSTON MEDICAL CENTER   (United States)

^b BOSTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Cervical cancer; Depression; Health maintenance; Inflammatory bowel disease; Osteoporosis; Prevention; Screening; Smoking; Vaccine

Indexed keywords

AZATHIOPRINE; CHICKENPOX VACCINE; CORTICOSTEROID; DIPHTHERIA VACCINE; GLUCOCORTICOID; HAEMOPHILUS INFLUENZAE TYPE B VACCINE; HEPATITIS A HEPATITIS B VACCINE; HEPATITIS B VACCINE; IMMUNOMODULATING AGENT; INFLIXIMAB; INFLUENZA VACCINE; MEASLES MUMPS RUBELLA VACCINE; MENINGOCOCCUS VACCINE; MERCAPTOPURINE; MESALAZINE; METHOTREXATE; PNEUMOCOCCUS VACCINE; TETANUS TOXOID; VARICELLA ZOSTER VACCINE; WART VIRUS VACCINE;

ANTIBODY TITER; BONE DENSITY; CANCER RISK; CANCER SCREENING; COLORECTAL CANCER; CROHN DISEASE; DEPRESSION; DRUG EFFICACY; DRUG ERUPTION; DRUG SAFETY; DUAL ENERGY X RAY ABSORPTIOMETRY; ENTERITIS; GENERAL PRACTITIONER; HEALTH SERVICE; HERPES ZOSTER; HUMAN; IMMUNE RESPONSE; IMMUNOSUPPRESSIVE TREATMENT; INFLUENZA; OSTEOPENIA; OSTEOPOROSIS; PAPANICOLAOU TEST; PROTEIN CALORIE MALNUTRITION; REVIEW; SIDE EFFECT; SKIN CANCER; SMOKING CESSATION; ULCERATIVE COLITIS; UTERINE CERVIX CANCER; VACCINATION;

HEALTH PROMOTION; HUMANS; INFLAMMATORY BOWEL DISEASES; NEEDS ASSESSMENT; PREVENTIVE HEALTH SERVICES;

EID: 84859647692     PISSN: 08898553     EISSN: 15581942     Source Type: Journal    
DOI: 10.1016/j.gtc.2012.01.006     Document Type: Review

References (63)

1. Selby L., Kane S., Wilson J., et al. Receipt of preventive health services by IBD patients is significantly lower than by primary care patients. Inflamm Bowel Dis 2008, 14:253-258.
2. Keene J.K., Lowe D.K., Grosfeld J.L., et al. Disseminated varicella complicating ulcerative colitis. JAMA 1978, 239:45-46.
3. Domm S., Cinatl J., Mrowietz U. The impact of treatment with tumour necrosis factor-alpha antagonists on the course of chronic viral infections: a review of the literature. Br J Dermatol 2008, 159:1217-1228.
4. Melmed G.Y., Ippoliti A.F., Papadakis K.A., et al. Patients with inflammatory bowel disease are at risk for vaccine-preventable illnesses. Am J Gastroenterol 2006, 101:1834-1840.
5. Selby L, Hoellein A, Wilson JF. Are primary care providers uncomfortable providing routine preventive care for inflammatory bowel disease patients? Dig Dis Sci 56:819-24.
6. Wasan S.K., Coukos J.A., Farraye F.A. Vaccinating the inflammatory bowel disease patient: deficiencies in gastroenterologists knowledge. Inflamm Bowel Dis 2011, 17:2536-2540.
7. Wasan SK, Baker SE, Skolnik PR, et al. A practical guide to vaccinating the inflammatory bowel disease patient. Am J Gastroenterol 105:1231-8.
8. Del Porto F., Lagana B., Biselli R., et al. Influenza vaccine administration in patients with systemic lupus erythematosus and rheumatoid arthritis. Safety and immunogenicity. Vaccine 2006, 24:3217-3223.
9. Fomin I., Caspi D., Levy V., et al. Vaccination against influenza in rheumatoid arthritis: the effect of disease modifying drugs, including TNF alpha blockers. Ann Rheum Dis 2006, 65:191-194.
10. Kaine J.L., Kivitz A.J., Birbara C., et al. Immune responses following administration of influenza and pneumococcal vaccines to patients with rheumatoid arthritis receiving adalimumab. J Rheumatol 2007, 34:272-279.
11. Chalmers A., Scheifele D., Patterson C., et al. Immunization of patients with rheumatoid arthritis against influenza: a study of vaccine safety and immunogenicity. J Rheumatol 1994, 21:1203-1206.
12. Kwon O.S., Park Y.S., Choi J.H., et al. A case of ulcerative colitis relapsed by influenza vaccination. Korean J Gastroenterol 2007, 49:327-330.
13. Fields S.W., Baiocco P.J., Korelitz B.I. Influenza vaccinations: should they really be encouraged for IBD patients being treated with immunosuppressives?. Inflamm Bowel Dis 2009, 15:649-651.
14. Debruyn J.C., Hilsden R., Fonseca K., et al. Immunogenicity and safety of influenza vaccination in children with inflammatory bowel disease. Inflamm Bowel Dis 2012, 18:25-33.
15. Rahier J.F., Papay P., Salleron J., et al. H1N1 vaccines in a large observational cohort of patients with inflammatory bowel disease treated with immunomodulators and biological therapy. Gut 2011, 60:456-462.
16. Dotan I., Vigodman S., Malter L., et al. Azathioprine (AZA)/6-mercaptopurine (6MP) therapy has NO significant effect on cellular or humoral immune responses in patients with inflammatory bowel disease. Gastroenterology 2007, 132:A51.
17. Melmed GY, Agarwal N, Frenck RW, et al. Immunosuppression impairs response to pneumococcal polysaccharide vaccination in patients with inflammatory bowel disease. Am J Gastroenterol 105:148-54.
18. Mamula P., Markowitz J.E., Piccoli D.A., et al. Immune response to influenza vaccine in pediatric patients with inflammatory bowel disease. Clin Gastroenterol Hepatol 2007, 5:851-856.
19. Cullen G., Bader C., Korzenik J.R., et al. Serological response to the 2009 H1N1 influenza vaccination in patients with inflammatory bowel disease. Gut 2011, [Epub ahead of print].
20. Donati M., Zuckerman M., Dhawan A., et al. Response to varicella immunization in pediatric liver transplant recipients. Transplantation 2000, 70:1401-1404.
21. Giebink G.S., Warkentin P.I., Ramsay N.K., et al. Titers of antibody to pneumococci in allogeneic bone marrow transplant recipients before and after vaccination with pneumococcal vaccine. J Infect Dis 1986, 154:590-596.
22. Sands B.E., Cuffari C., Katz J., et al. Guidelines for immunizations in patients with inflammatory bowel disease. Inflamm Bowel Dis 2004, 10:677-692.
23. Watson J.C., Hadler S.C., Dykewicz C.A., et al. Measles, mumps, and rubella: vaccine use and strategies for elimination of measles, rubella, and congenital rubella syndrome and control of mumps: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep 1998, 47:1-57.
24. Kotton C.N. Nailing down the shingles in IBD. Inflamm Bowel Dis 2007, 13:1178-1179.
25. Gupta G., Lautenbach E., Lewis J.D. Incidence and risk factors for herpes zoster among patients with inflammatory bowel disease. Clin Gastroenterol Hepatol 2006, 4:1483-1490.
26. Harpaz R., Ortega-Sanchez I.R., Seward J.F. Prevention of herpes zoster: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep 2008, 57:1-30.
27. Singh A., Englund K. Q: who should receive the shingles vaccine?. Cleve Clin J Med 2009, 76:45-48.
28. Fiore A.E., Uyeki T.M., Broder K., et al. Prevention and control of influenza with vaccines: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep 2010, 59:1-62.
29. Nielsen H.J., Mortensen T., Holten-Andersen M., et al. Increased levels of specific leukocyte- and platelet-derived substances during normal anti-tetanus antibody synthesis in patients with inactive Crohn disease. Scand J Gastroenterol 2001, 36:265-269.
30. Brogan M.D., Shanahan F., Oliver M., et al. Defective memory B cell formation in patients with inflammatory bowel disease following tetanus toxoid booster immunization. J Clin Lab Immunol 1987, 24:69-74.
31. Recommended adult immunization schedule: United States, 2009*. Ann Intern Med 2009, 150:40-44.
32. Mitchell D. ACIP Expands HPV vaccine recommendation to adolescent boys [updated 2011], Accessed November 3, 2011. http://www.aafp.org/online/en/home/publications/news/news-now/health-of-the-public/20111026acip-hpv-hepb.html.
33. Kane S. Abnormal Pap smears in inflammatory bowel disease. Inflamm Bowel Dis 2008, 14:1158-1160.
34. Kane S., Khatibi B., Reddy D. Higher incidence of abnormal Pap smears in women with inflammatory bowel disease. Am J Gastroenterol 2008, 103:631-636.
35. Esteve M., Saro C., Gonzalez-Huix F., et al. Chronic hepatitis B reactivation following infliximab therapy in Crohn's disease patients: need for primary prophylaxis. Gut 2004, 53:1363-1365.
36. Montiel P.M., Solis J.A., Chirinos J.A., et al. Hepatitis B virus reactivation during therapy with etanercept in an HBsAg-negative and anti-HBs-positive patient. Liver Int 2008, 28:718-720.
37. Vida Perez L., Gomez Camacho F., Garcia Sanchez V., et al. Adequate rate of response to hepatitis B virus vaccination in patients with inflammatory bowel disease. Med Clin (Barc) 2009, 132:331-335.
38. Cardell K., Akerlind B., Sallberg M., et al. Excellent response rate to a double dose of the combined hepatitis A and B vaccine in previous nonresponders to hepatitis B vaccine. J Infect Dis 2008, 198:299-304.
39. Lees C.W., Critchley J., Chee N., et al. Lack of association between cervical dysplasia and IBD: a large case-control study. Inflamm Bowel Dis 2009, 15:1621-1629.
40. Singh H., Demers A.A., Nugent Z., et al. Risk of cervical abnormalities in women with inflammatory bowel disease: a population-based nested case-control study. Gastroenterology 2009, 136:451-458.
41. Cervical cytology screening. Obstet Gynecol 2009, 114:1409-1420. ACOG Practice Bulletin no. 109.
42. Bernstein C.N., Leslie W.D., Leboff M.S. AGA technical review on osteoporosis in gastrointestinal diseases. Gastroenterology 2003, 124:795-841.
43. Lichtenstein G.R., Sands B.E., Pazianas M. Prevention and treatment of osteoporosis in inflammatory bowel disease. Inflamm Bowel Dis 2006, 12:797-813.
44. Etzel JP, Larson MF, Anawalt BD, et al. Assessment and management of low bone density in inflammatory bowel disease and performance of professional society guidelines. Inflamm Bowel Dis 17:2122-9.
45. Kornbluth A., Hayes M., Feldman S., et al. Do guidelines matter?. Implementation of the ACG and AGA osteoporosis screening guidelines in inflammatory bowel disease (IBD) patients who meet the guidelines' criteria. Am J Gastroenterol 2006, 101:1546-1550.
46. Raisz L.G. Clinical practice. Screening for osteoporosis. N Engl J Med 2005, 353:164-171.
47. guidelines on osteoporosis in gastrointestinal diseases. Gastroenterology 2003, 124:791-794. American Gastroenterological Association medical position statement.
48. Farraye FA, Odze RD, Eaden J, et al. AGA technical review on the diagnosis and management of colorectal neoplasia in inflammatory bowel disease. Gastroenterology 138:746-74.
49. Farraye FA, Odze RD, Eaden J, et al. AGA medical position statement on the diagnosis and management of colorectal neoplasia in inflammatory bowel disease. Gastroenterology 138:738-45.
50. Kornbluth A, Sachar DB. Ulcerative colitis practice guidelines in adults: American College of Gastroenterology, Practice Parameters Committee. Am J Gastroenterol 105:501-23.
51. Ullman T., Odze R., Farraye F.A. Diagnosis and management of dysplasia in patients with ulcerative colitis and Crohn's disease of the colon. Inflamm Bowel Dis 2009, 15:630-638.
52. Cairns SR, Scholefield JH, Steele RJ, et al. Guidelines for colorectal cancer screening and surveillance in moderate and high risk groups (update from 2002). Gut 59:666-89.
53. Rubin C.E., Haggitt R.C., Burmer G.C., et al. DNA aneuploidy in colonic biopsies predicts future development of dysplasia in ulcerative colitis. Gastroenterology 1992, 103:1611-1620.
54. Long MD, Kappelman MD, Pipkin CA. Nonmelanoma skin cancer in inflammatory bowel disease: a review. Inflamm Bowel Dis 17:1423-7.
55. Long MD, Herfarth HH, Pipkin CA, et al. Increased risk for non-melanoma skin cancer in patients with inflammatory bowel disease. Clin Gastroenterol Hepatol 8:268-74.
56. Peyrin-Biroulet L., Khosrotehrani K., Carrat F., et al. Increased risk for nonmelanoma skin cancers in patients who receive thiopurines for inflammatory bowel disease. Gastroenterology 2011, 141:28.e1-28.e5. 1621.
57. Screening for skin cancer: U.S. Preventive Services Task Force recommendation statement. Ann Intern Med 2009, 150:188-193.
58. Cosnes J. What is the link between the use of tobacco and IBD?. Inflamm Bowel Dis 2008, 14(Suppl 2):S14-S15.
59. Graff L.A., Walker J.R., Bernstein C.N. Depression and anxiety in inflammatory bowel disease: a review of comorbidity and management. Inflamm Bowel Dis 2009, 15:1105-1118.
60. Graff L.A., Walker J.R., Clara I., et al. Stress coping, distress, and health perceptions in inflammatory bowel disease and community controls. Am J Gastroenterol 2009, 104:2959-2969.
61. Walker J.R., Ediger J.P., Graff L.A., et al. The Manitoba IBD cohort study: a population-based study of the prevalence of lifetime and 12-month anxiety and mood disorders. Am J Gastroenterol 2008, 103:1989-1997.
62. Nimalasuriya K., Compton M.T., Guillory V.J. Screening adults for depression in primary care: A position statement of the American College of Preventive Medicine. J Fam Pract 2009, 58:535-538.
63. Kappelman MD, Palmer L, Boyle BM, et al. Quality of care in inflammatory bowel disease: a review and discussion. Inflamm Bowel Dis 16:125-33.